Targeting TRD and adjunctive MDD with a novel mode of action

The Nelivabon program is a first-in-class oral vasopressin V1b receptor antagonist targeting the human body’s stress axis (HPA-axis) for adjunctive treatment of Major Depressive Disorder (MDD) patients without the side effects associated with antipsychotic augmentation.

The neuropeptide vasopressin coordinates hormonal and behavioral adaptation to stress. Repeated stressors cause an elevated activity of vasopressin in the brain, potentially resulting in an increase of anxiety and a major depressive episode. Nelivaptan is an antagonist at the vasopressin V1b receptor, expected to be able to treat this dysfunction.

HMNC Brain Health is advancing the Nelivabon program for the treatment of TRD and adjunctive MDD toward Phase 3 readiness.